121 related articles for article (PubMed ID: 35905589)
21. siRNA delivery by a transferrin-associated lipid-based vector: a non-viral strategy to mediate gene silencing.
Cardoso AL; Simões S; de Almeida LP; Pelisek J; Culmsee C; Wagner E; Pedroso de Lima MC
J Gene Med; 2007 Mar; 9(3):170-83. PubMed ID: 17351968
[TBL] [Abstract][Full Text] [Related]
22. Heavy chain ferritin siRNA delivered by cationic liposomes increases sensitivity of cancer cells to chemotherapeutic agents.
Liu X; Madhankumar AB; Slagle-Webb B; Sheehan JM; Surguladze N; Connor JR
Cancer Res; 2011 Mar; 71(6):2240-9. PubMed ID: 21385903
[TBL] [Abstract][Full Text] [Related]
23. Insights into the therapeutic potential of hypoxia-inducible factor-1α small interfering RNA in malignant melanoma delivered via folate-decorated cationic liposomes.
Chen Z; Zhang T; Wu B; Zhang X
Int J Nanomedicine; 2016; 11():991-1002. PubMed ID: 27042054
[TBL] [Abstract][Full Text] [Related]
24. Ultrasound-Guided Delivery of siRNA and a Chemotherapeutic Drug by Using Microbubble Complexes: In Vitro and In Vivo Evaluations in a Prostate Cancer Model.
Bae YJ; Yoon YI; Yoon TJ; Lee HJ
Korean J Radiol; 2016; 17(4):497-508. PubMed ID: 27390541
[TBL] [Abstract][Full Text] [Related]
25. Aptamer-functionalized liposomes for targeted cancer therapy.
Moosavian SA; Sahebkar A
Cancer Lett; 2019 Apr; 448():144-154. PubMed ID: 30763718
[TBL] [Abstract][Full Text] [Related]
26. pH-Sensitive carboxymethyl chitosan-modified cationic liposomes for sorafenib and siRNA co-delivery.
Yao Y; Su Z; Liang Y; Zhang N
Int J Nanomedicine; 2015; 10():6185-97. PubMed ID: 26491291
[TBL] [Abstract][Full Text] [Related]
27. Novel and efficient method for loading aptamer-conjugated liposomes with arsenic trioxide for targeting cancer cells.
Mirveis Z; Kouchak M; Mahdavinia M; Rahbar N
J Liposome Res; 2022 Sep; 32(3):276-283. PubMed ID: 34918592
[TBL] [Abstract][Full Text] [Related]
28. Co-delivery of Bmi1 small interfering RNA with ursolic acid by folate receptor-targeted cationic liposomes enhances anti-tumor activity of ursolic acid
Li W; Yan R; Liu Y; He C; Zhang X; Lu Y; Khan MW; Xu C; Yang T; Xiang G
Drug Deliv; 2019 Dec; 26(1):794-802. PubMed ID: 31366257
[TBL] [Abstract][Full Text] [Related]
29. cRGD grafted liposomes containing inorganic nano-precipitate complexed siRNA for intracellular delivery in cancer cells.
Khatri N; Baradia D; Vhora I; Rathi M; Misra A
J Control Release; 2014 May; 182():45-57. PubMed ID: 24631861
[TBL] [Abstract][Full Text] [Related]
30. Codelivery of doxorubicin and JIP1 siRNA with novel EphA2-targeted PEGylated cationic nanoliposomes to overcome osteosarcoma multidrug resistance.
Haghiralsadat F; Amoabediny G; Naderinezhad S; Zandieh-Doulabi B; Forouzanfar T; Helder MN
Int J Nanomedicine; 2018; 13():3853-3866. PubMed ID: 30013340
[TBL] [Abstract][Full Text] [Related]
31. Anti-EphA10 antibody-conjugated pH-sensitive liposomes for specific intracellular delivery of siRNA.
Zang X; Ding H; Zhao X; Li X; Du Z; Hu H; Qiao M; Chen D; Deng Y; Zhao X
Int J Nanomedicine; 2016; 11():3951-67. PubMed ID: 27574425
[TBL] [Abstract][Full Text] [Related]
32. Aptamer-Functionalized Liposomes as a Potential Treatment for Basal Cell Carcinoma.
Cadinoiu AN; Rata DM; Atanase LI; Daraba OM; Gherghel D; Vochita G; Popa M
Polymers (Basel); 2019 Sep; 11(9):. PubMed ID: 31540426
[TBL] [Abstract][Full Text] [Related]
33. Novel cationic cholesterol derivative-based liposomes for serum-enhanced delivery of siRNA.
Han SE; Kang H; Shim GY; Suh MS; Kim SJ; Kim JS; Oh YK
Int J Pharm; 2008 Apr; 353(1-2):260-9. PubMed ID: 18178348
[TBL] [Abstract][Full Text] [Related]
34. Galactose-modified cationic liposomes as a liver-targeting delivery system for small interfering RNA.
Sonoke S; Ueda T; Fujiwara K; Kuwabara K; Yano J
Biol Pharm Bull; 2011; 34(8):1338-42. PubMed ID: 21804229
[TBL] [Abstract][Full Text] [Related]
35. Formulations Based on Drug Loaded Aptamer-Conjugated Liposomes as a Viable Strategy for the Topical Treatment of Basal Cell Carcinoma-In Vitro Tests.
Cadinoiu AN; Rata DM; Atanase LI; Mihai CT; Bacaita SE; Popa M
Pharmaceutics; 2021 Jun; 13(6):. PubMed ID: 34208362
[TBL] [Abstract][Full Text] [Related]
36. Liposomal nanocarriers containing siRNA as small molecule-based drugs to overcome cancer drug resistance.
Safaei M; Khalighi F; Behabadi FA; Abpeikar Z; Goodarzi A; Kouhpayeh SA; Najafipour S; Ramezani V
Nanomedicine (Lond); 2023 Oct; 18(24):1745-1768. PubMed ID: 37965906
[TBL] [Abstract][Full Text] [Related]
37. Co-delivery of curcumin and STAT3 siRNA using deformable cationic liposomes to treat skin cancer.
Jose A; Labala S; Venuganti VV
J Drug Target; 2017 Apr; 25(4):330-341. PubMed ID: 27819148
[TBL] [Abstract][Full Text] [Related]
38. Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin.
Jiang J; Yang SJ; Wang JC; Yang LJ; Xu ZZ; Yang T; Liu XY; Zhang Q
Eur J Pharm Biopharm; 2010 Oct; 76(2):170-8. PubMed ID: 20600887
[TBL] [Abstract][Full Text] [Related]
39. Radiosensitization of breast cancer cells using AS1411 aptamer-conjugated gold nanoparticles.
Mehrnia SS; Hashemi B; Mowla SJ; Nikkhah M; Arbabi A
Radiat Oncol; 2021 Feb; 16(1):33. PubMed ID: 33568174
[TBL] [Abstract][Full Text] [Related]
40. Aptamer (AS1411)-Conjugated Liposome for Enhanced Therapeutic Efficacy of miRNA-29b in Ovarian Cancer.
Jiang L; Wang H; Chen S
J Nanosci Nanotechnol; 2020 Apr; 20(4):2025-2031. PubMed ID: 31492208
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
